Pega-One
Pre-clinicalImgatuzumab, is a second-generation Anti-EGFR Tumor-Targeting mAb utilizing Glycoengineering technology from Glycart, which provides enhanced ADCC (Antibody Derived Cell Cytotoxicity) and ADCP (Antibody Dependent Cellular Phagocytosis) developed by Roche and licensed by Pega-One.
Founded
2019
Focus
AntibodiesBiologics
About
Imgatuzumab, is a second-generation Anti-EGFR Tumor-Targeting mAb utilizing Glycoengineering technology from Glycart, which provides enhanced ADCC (Antibody Derived Cell Cytotoxicity) and ADCP (Antibody Dependent Cellular Phagocytosis) developed by Roche and licensed by Pega-One.
Funding History
1Total raised: $2.8M
Seed$2.8MUndisclosedSep 15, 2021
Company Info
TypePrivate
Founded2019
LocationParis, France
StagePre-clinical
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile